LENVIMA is a kinase inhibitor that is indicated:
Differentiated Thyroid Cancer (DTC):
*For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
Renal Cell Carcinoma (RCC):
*In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC).
*In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy.
Hepatocellular Carcinoma (HCC):
*For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Endometrial Carcinoma (EC):
*In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR), as determined by an FDA-approved test, or not microsatellite instability-high (MSI-H), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
